What is Trinity Biotech's operating income?

Trinity Biotech's total operating income in 2025 was -$11.72 million, based on the following breakdown: Total Gross Profit: $16.89 million Total Operating Expenses: $28.61 million

Trinity Biotech (TRIB) Financials

$8.45 -0.51 (-5.73%)

Closing price 07/24/2026 03:51 PM Eastern

Extended Trading

$8.34 -0.11 (-1.30%)

As of 07/24/2026 07:34 PM Eastern

Compare

Annual Income Statements for Trinity Biotech

This table shows Trinity Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	22	-42	-40	-23	-29	-6.01	-1.85	-44	-37	-25	-33
Consolidated Net Income / (Loss)	22	-42	-39	-23	-29	-6.01	-1.85	-44	-37	-25	-33
Net Income / (Loss) Continuing Operations	22	-42	-39	-23	-29	-6.01	-1.85	-44	-37	-25	-33
Total Pre-Tax Income	23	-42	-40	-23	-30	-6.63	-1.92	-44	-37	-31	-37
Total Operating Income	14	-45	-38	-20	-24	-6.67	3.94	-19	-27	-15	-12
Total Gross Profit	47	38	42	41	38	49	33	17	19	21	17
Total Revenue	100	100	99	97	90	102	81	63	57	62	44
Operating Revenue	100	100	99	97	90	102	81	63	57	62	44
Total Cost of Revenue	54	62	57	56	52	53	48	45	37	40	27
Operating Cost of Revenue	54	62	57	56	52	53	48	45	37	40	27
Total Operating Expenses	37	83	85	67	69	55	37	61	46	37	29
Selling, General & Admin Expense	28	30	32	29	28	27	23	27	31	29	25
Research & Development Expense	5.07	5.04	5.66	5.37	5.33	5.08	4.50	4.14	4.38	4.54	3.63
Other Operating Expenses / (Income)	3.77	-0.24	5.31	4.98	12	4.89	2.66	24	-0.14	1.79	-1.87
Impairment Charge	0.00	48	42	27	24	18	6.94	5.84	11	1.41	2.18
Total Other Income / (Expense), net	13	3.15	3.20	2.12	0.70	0.04	1.22	0.30	-9.88	-9.57	-21
Interest & Investment Income	-	3.15	-	-	-	-	-	-	1.17	0.00	0.00
Other Income / (Expense), net	13	-	3.20	2.12	0.70	0.04	1.22	0.30	-11	-9.57	-21
Income Tax Expense	0.76	-	-1.21	-0.53	-1.01	-0.62	-0.07	-0.19	-0.06	0.49	0.20
Basic Earnings per Share	-	-	-	-	-	-	-	-	($0.20)	($0.10)	($0.10)
Weighted Average Basic Shares Outstanding	-	-	96.16M	96.16M	83.61M	83.61M	83.61M	152.43M	153.31M	359.19M	374.21M
Diluted Earnings per Share	-	-	-	-	-	-	-	-	($0.20)	($0.10)	($0.10)
Weighted Average Diluted Shares Outstanding	-	-	96.16M	96.16M	83.61M	83.61M	83.61M	152.43M	153.31M	359.19M	374.21M
Weighted Average Basic & Diluted Shares Outstanding	-	-	96.16M	96.16M	83.61M	83.61M	83.61M	152.43M	153.31M	359.19M	374.21M

No quarterly income statements for Trinity Biotech are available.

This table details how cash moves in and out of Trinity Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	93	-25	-20	-27	-14	11	-1.47	-19	-4.22	27	-0.10
Net Cash From Operating Activities	13	-10	-9.25	-7.23	5.42	24	13	-0.92	0.83	-3.07	-5.93
Net Cash From Continuing Operating Activities	14	13	11	6.40	5.42	24	13	-0.92	0.83	-3.07	-6.12
Net Income / (Loss) Continuing Operations	22	-101	-40	-22	-29	-6.39	0.88	-41	0.00	0.00	-37
Consolidated Net Income / (Loss)	22	-101	-40	-22	-29	-6.39	0.88	-41	-	-	-37
Depreciation Expense	2.99	3.16	1.90	1.30	2.53	1.67	1.83	1.41	0.83	0.68	1.30
Amortization Expense	2.65	2.97	3.30	2.83	2.37	1.40	0.92	0.92	-	-	1.39
Non-Cash Adjustments To Reconcile Net Income	-7.48	107	45	31	31	24	8.18	32	0.00	-3.75	23
Changes in Operating Assets and Liabilities, net	-5.87	0.34	1.43	-6.97	-1.25	3.23	1.44	5.72	-	-	6.06
Net Cash From Investing Activities	-28	-22	-16	-17	-12	-10	-8.69	-5.98	0.00	0.00	-6.22
Net Cash From Continuing Investing Activities	-28	-22	-16	-17	-12	-10	-8.69	-5.98	0.00	0.00	-6.22
Purchase of Property, Plant & Equipment	-27	-21	-15	-17	-12	-10	-8.69	-5.98	-	-	-6.22
Sale of Property, Plant & Equipment	-	-	-	-	-	-	0.00	0.00	-	-	0.00
Net Cash From Financing Activities	108	-13	-13	-17	-7.53	-2.72	-6.02	-12	-5.05	30	12
Net Cash From Continuing Financing Activities	108	-13	-13	-17	-7.53	-2.72	-6.02	-22	-5.05	30	12
Repayment of Debt	-2.34	-4.88	-4.60	-17	-7.53	-7.24	-6.94	-125	-10	0.00	-3.20
Issuance of Debt	113	0.86	0.00	0.00	0.00	4.52	1.76	80	5.00	30	15
Issuance of Common Equity	-0.01	-0.01	0.00	-	-	0.00	0.00	25	-	-	0.55

No quarterly cash flow statements for Trinity Biotech are available.

This table presents Trinity Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	250	193	152	131	130	119	92	59	103	105
Total Current Assets	133	113	87	71	83	73	47	39	41	36
Cash & Equivalents	77	24	30	15	27	26	6.58	3.69	5.17	5.14
Accounts Receivable	23	21	24	21	23	16	16	14	16	11
Inventories, net	33	33	30	32	30	29	23	20	19	19
Current Deferred & Refundable Income Taxes	1.21	1.44	1.58	1.98	3.09	1.54	1.83	1.52	0.52	0.46
Plant, Property, & Equipment, net	13	5.80	5.36	9.29	8.55	5.92	-41	1.89	4.62	-60
Plant, Property & Equipment, gross	13	5.80	5.36	9.29	8.55	5.92	-41	1.89	4.62	-60
Total Noncurrent Assets	103	75	60	50	39	40	40	19	55	64
Goodwill	-	-	-	-	-	-	35	-	-	57
Noncurrent Deferred & Refundable Income Taxes	15	8.70	6.13	6.25	4.19	4.10	4.22	1.98	3.55	3.92
Other Noncurrent Operating Assets	0.87	1.13	0.56	0.49	0.51	0.21	0.27	0.26	0.19	3.05
Total Liabilities & Shareholders' Equity	250	193	152	131	130	119	46	59	103	41
Total Liabilities	141	128	108	126	133	119	94	83	138	177
Total Current Liabilities	25	21	18	19	27	100	16	15	32	30
Short-Term Debt	-	-	-	-	-	-	0.21	0.21	0.21	0.21
Accounts Payable	25	21	17	17	24	15	15	13	27	30
Current Deferred & Payable Income Tax Liabilities	0.18	0.31	0.21	0.05	0.15	0.02	0.03	0.28	0.36	0.35
Total Noncurrent Liabilities	116	107	90	107	106	19	79	68	106	146
Long-Term Debt	92	93	81	82	1.37	-	58	55	88	124
Capital Lease Obligations	0.73	0.53	0.53	18	17	14	14	11	10	13
Noncurrent Deferred & Payable Income Tax Liabilities	18	11	7.86	7.14	4.91	4.86	5.06	2.30	4.56	4.67
Other Noncurrent Operating Liabilities	4.26	2.23	0.24	0.00	-	0.00	1.57	0.53	1.66	3.32
Total Equity & Noncontrolling Interests	109	65	44	4.71	-2.22	-0.32	-49	-24	-35	-136
Total Preferred & Common Equity	109	65	44	4.71	-2.22	-0.32	-49	-24	-35	-136
Total Common Equity	93	49	28	-11	-18	-17	-49	-71	-99	-136
Common Stock	1.21	1.21	1.21	1.21	1.21	1.21	1.96	1.97	4.19	0.04
Retained Earnings	110	76	55	16	11	13	-27	-49	-79	-116
Treasury Stock	-17	-25	-25	-25	-25	-25	-25	-25	-25	-25
Other Equity Adjustments	-1.78	-3.22	-3.74	-3.91	-5.27	-5.36	1.02	1.03	1.27	5.27

No quarterly balance sheets for Trinity Biotech are available.

This table displays calculated financial ratios and metrics derived from Trinity Biotech's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	96,162,410.00	96,162,410.00	83,606,810.00	83,606,810.00	83,606,810.00	152,430,284.00	153,310,284.00	359,193,482.00	374,206,640.00
DEI Adjusted Shares Outstanding	0.00	0.00	3,846,496.00	3,846,496.00	3,344,272.00	3,344,272.00	3,344,272.00	6,097,211.00	6,132,411.00	71,838,696.00	374,206,640.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	-10.47	-5.89	-8.67	-1.80	-0.55	-7.15	-6.01	-0.35	-0.09
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-0.58%	-0.47%	-2.12%	-6.80%	12.86%	-20.49%	-22.96%	-9.10%	8.31%	-28.87%
EBITDA Growth	0.00%	-219.96%	25.24%	52.23%	-32.46%	80.80%	322.30%	-311.42%	-122.98%	35.59%	-26.77%
EBIT Growth	0.00%	-267.75%	23.89%	47.48%	-29.34%	71.67%	177.81%	-469.04%	-100.03%	35.23%	-34.18%
NOPAT Growth	0.00%	-342.71%	16.82%	46.30%	-19.21%	72.34%	159.05%	-591.34%	-39.77%	44.12%	22.43%
Net Income Growth	0.00%	-289.93%	8.26%	41.39%	-27.95%	79.26%	69.23%	-2,256.00%	15.41%	31.75%	-32.38%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	31.75%	0.00%
Operating Cash Flow Growth	0.00%	-177.74%	9.56%	21.85%	174.93%	338.53%	-44.27%	-106.96%	190.23%	-469.92%	-92.88%
Free Cash Flow Firm Growth	0.00%	0.00%	98.17%	-206.40%	-5.75%	232.69%	-76.30%	1,286.19%	-199.06%	24.95%	274.03%
Invested Capital Growth	0.00%	0.00%	-18.87%	-5.33%	-7.95%	-19.27%	-0.22%	-76.06%	124.23%	51.11%	-105.10%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	46.42%	38.19%	42.25%	42.72%	42.15%	47.60%	41.23%	27.62%	34.22%	34.83%	38.57%
EBITDA Margin	32.58%	-39.31%	-29.52%	-14.41%	-20.48%	-3.48%	9.74%	-26.73%	-65.57%	-38.99%	-69.49%
Operating Margin	13.48%	-45.46%	-37.99%	-20.85%	-26.66%	-6.53%	4.85%	-30.95%	-47.59%	-24.55%	-26.77%
EBIT Margin	26.94%	-45.46%	-34.77%	-18.66%	-25.89%	-6.50%	6.36%	-30.46%	-67.04%	-40.09%	-75.62%
Profit (Net Income) Margin	22.14%	-42.30%	-39.00%	-23.35%	-32.06%	-5.89%	-2.28%	-69.71%	-64.87%	-40.88%	-76.08%
Tax Burden Percent	96.70%	100.00%	96.96%	97.74%	96.65%	90.65%	96.15%	99.56%	99.84%	81.88%	89.60%
Interest Burden Percent	84.98%	93.05%	115.68%	128.06%	128.11%	100.00%	-37.28%	229.86%	96.93%	124.53%	112.28%
Effective Tax Rate	3.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-50.89%	-23.37%	-14.39%	-18.37%	-5.87%	3.88%	-30.80%	-68.74%	-22.12%	-30.04%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-182.57%	-70.89%	-33.82%	-36.31%	-7.58%	-2.49%	-74.70%	-96.84%	-40.96%	-52.30%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-26.62%	-21.09%	-27.09%	-100.53%	-476.33%	141.90%	208.88%	170.33%	107.23%	69.01%
Return on Equity (ROE)	0.00%	-77.52%	-44.46%	-41.48%	-118.90%	-482.20%	145.78%	178.07%	101.59%	85.11%	38.97%
Cash Return on Invested Capital (CROIC)	0.00%	-250.89%	-2.54%	-8.91%	-10.09%	15.46%	4.10%	91.92%	-145.37%	-62.83%	0.00%
Operating Return on Assets (OROA)	0.00%	-18.14%	-15.58%	-10.51%	-16.56%	-5.07%	4.14%	-18.05%	-50.28%	-30.33%	-31.77%
Return on Assets (ROA)	0.00%	-16.88%	-17.47%	-13.15%	-20.51%	-4.60%	-1.48%	-41.31%	-48.66%	-30.93%	-31.96%
Return on Common Equity (ROCE)	0.00%	-65.98%	-36.18%	-29.19%	-39.97%	5,777.09%	2,005.36%	236.96%	166.84%	243.47%	53.42%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-38.76%	-59.30%	-51.43%	-615.13%	270.98%	579.94%	89.62%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	13	-32	-26	-14	-17	-4.67	2.76	-14	-19	-11	-8.21
NOPAT Margin	13.04%	-31.82%	-26.60%	-14.59%	-18.66%	-4.57%	3.40%	-21.66%	-33.31%	-17.19%	-18.74%
Net Nonoperating Expense Percent (NNEP)	0.00%	131.68%	47.52%	19.42%	17.95%	1.72%	6.37%	43.89%	28.10%	18.84%	22.26%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-57.47%	-45.31%	-16.71%	-372.84%
Cost of Revenue to Revenue	53.58%	61.81%	57.75%	57.28%	57.85%	52.32%	58.77%	72.38%	65.78%	65.17%	61.43%
SG&A Expenses to Revenue	28.17%	30.48%	32.53%	30.38%	30.59%	26.94%	27.73%	43.16%	54.81%	46.81%	56.35%
R&D to Revenue	5.06%	5.06%	5.71%	5.53%	5.89%	4.98%	5.54%	6.62%	7.71%	7.38%	8.29%
Operating Expenses to Revenue	36.99%	83.66%	85.70%	68.80%	76.09%	54.13%	45.10%	98.13%	81.81%	59.38%	65.34%
Earnings before Interest and Taxes (EBIT)	27	-45	-34	-18	-23	-6.63	5.16	-19	-38	-25	-33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	33	-39	-29	-14	-19	-3.56	7.91	-17	-37	-24	-30
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	1.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.57	0.27	0.78	0.37	0.33	0.29	0.55	0.32
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	1.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	1.28	1.41	1.22	0.48	5.08	3.28	3.31	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	1.27	1.38	0.85	0.42	1.38	2.20	3.09	3.36
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	4.31	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	6.59	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	12.35	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	22.96	3.64	2.57	0.00	150.43	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	7.03	11.67	2.14	0.00	0.00	2.81
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.86	1.43	1.86	21.17	-8.09	-43.46	-1.48	-2.74	-2.80	-1.02
Long-Term Debt to Equity	0.00	0.86	1.43	1.86	21.17	-8.09	-43.46	-1.48	-2.74	-2.79	-1.01
Financial Leverage	0.00	0.15	0.30	0.80	2.77	62.83	-56.97	-2.80	-1.76	-2.62	-1.32
Leverage Ratio	0.00	2.30	2.54	3.15	5.80	104.84	-98.22	-4.31	-2.09	-2.75	-1.22
Compound Leverage Factor	0.00	2.14	2.94	4.04	7.43	104.84	36.62	-9.91	-2.02	-3.43	-1.37
Debt to Total Capital	0.00%	46.09%	58.91%	65.03%	95.49%	114.10%	102.35%	306.37%	157.32%	155.58%	6,269.11%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.89%	0.50%	0.33%	9.54%
Long-Term Debt to Total Capital	0.00%	46.09%	58.91%	65.03%	95.49%	114.10%	102.35%	305.48%	156.81%	155.25%	6,259.56%
Preferred Equity to Total Capital	0.00%	8.03%	10.20%	12.85%	15.49%	102.85%	119.50%	0.00%	111.57%	100.16%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	45.88%	30.88%	22.12%	-10.98%	-116.95%	-121.85%	-206.37%	-168.89%	-155.74%	-6,169.11%
Debt to EBITDA	0.00	-2.37	-3.19	-5.86	-5.39	-5.05	1.75	-4.32	-1.76	-4.10	-4.53
Net Debt to EBITDA	0.00	-0.40	-1.23	-3.69	-4.50	2.63	-1.52	-3.93	-1.66	-3.89	-4.37
Long-Term Debt to EBITDA	0.00	-2.37	-3.19	-5.86	-5.39	-5.05	1.75	-4.31	-1.76	-4.09	-4.53
Debt to NOPAT	0.00	-2.93	-3.55	-5.78	-5.91	-3.85	5.03	-5.33	-3.47	-9.31	-16.81
Net Debt to NOPAT	0.00	-0.50	-1.36	-3.65	-4.94	2.01	-4.37	-4.85	-3.28	-8.82	-16.19
Long-Term Debt to NOPAT	0.00	-2.93	-3.55	-5.78	-5.91	-3.85	5.03	-5.32	-3.46	-9.29	-16.79
Altman Z-Score	0.00	0.00	0.00	1.61	0.87	1.61	0.84	0.13	-1.70	-1.01	-2.06
Noncontrolling Interest Sharing Ratio	0.00%	14.89%	18.61%	29.63%	66.39%	1,298.08%	-1,275.57%	-33.07%	-64.23%	-186.06%	-37.08%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	5.28	5.30	4.92	3.67	3.08	0.72	2.99	2.60	1.28	1.19
Quick Ratio	0.00	3.94	3.69	3.11	1.92	1.85	0.42	1.43	1.17	0.66	0.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-156	-2.86	-8.77	-9.27	12	2.92	40	-40	-30	52
Operating Cash Flow to CapEx	49.48%	-49.26%	-61.39%	-41.57%	45.70%	232.94%	152.32%	-15.41%	0.00%	0.00%	-95.28%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.40	0.45	0.56	0.64	0.78	0.65	0.59	0.75	0.76	0.42
Accounts Receivable Turnover	0.00	4.41	4.58	4.30	3.98	4.68	4.18	3.92	3.83	4.11	3.18
Inventory Turnover	0.00	1.89	1.75	1.76	1.68	1.72	1.61	1.75	1.76	2.04	1.41
Fixed Asset Turnover	0.00	7.43	10.33	17.39	12.34	11.44	11.22	0.00	0.00	18.90	0.00
Accounts Payable Turnover	0.00	2.49	2.53	2.97	3.09	2.59	2.42	2.97	2.65	2.03	0.95
Days Sales Outstanding (DSO)	0.00	82.76	79.75	84.97	91.67	78.06	87.22	93.03	95.23	88.84	114.81
Days Inventory Outstanding (DIO)	0.00	193.21	208.46	207.38	217.61	212.71	227.07	208.20	207.17	178.83	259.20
Days Payable Outstanding (DPO)	0.00	146.77	144.32	122.87	118.10	141.09	151.00	123.01	137.56	180.09	383.24
Cash Conversion Cycle (CCC)	0.00	129.19	143.90	169.49	191.18	149.69	163.29	178.22	164.84	87.58	-9.24
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	125	101	96	88	71	71	17	38	58	-2.94
Invested Capital Turnover	0.00	1.60	0.88	0.99	0.98	1.28	1.14	1.42	2.06	1.29	1.60
Increase / (Decrease) in Invested Capital	0.00	125	-24	-5.39	-7.61	-17	-0.16	-54	21	19	-61
Enterprise Value (EV)	0.00	0.00	0.00	123	124	86	34	86	125	190	147
Market Capitalization	0.00	0.00	0.00	55	25	80	30	21	16	34	14
Book Value per Share	$0.00	$0.00	$0.51	$0.29	($0.12)	($0.22)	($0.20)	($0.32)	($0.46)	($0.27)	($0.38)
Tangible Book Value per Share	$0.00	$0.00	($0.16)	($0.26)	($0.57)	($0.63)	($0.63)	($0.55)	($0.57)	($0.42)	($0.54)
Total Capital	0.00	202	159	126	104	16	14	24	42	63	2.20
Total Debt	0.00	93	93	82	100	18	14	72	66	98	138
Total Long-Term Debt	0.00	93	93	82	100	18	14	72	66	98	138
Net Debt	0.00	16	36	52	83	-9.37	-12	66	62	93	133
Capital Expenditures (CapEx)	27	21	15	17	12	10	8.69	5.98	0.00	0.00	6.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	31	34	39	36	29	-54	25	21	4.07	0.71
Debt-free Net Working Capital (DFNWC)	0.00	108	91	69	52	56	-28	31	24	9.24	5.85
Net Working Capital (NWC)	0.00	108	91	69	52	56	-28	31	24	9.03	5.64
Net Nonoperating Expense (NNE)	-9.13	10	12	8.50	12	1.34	4.61	30	18	15	25
Net Nonoperating Obligations (NNO)	0.00	16	36	52	83	73	71	66	62	93	133
Total Depreciation and Amortization (D&A)	5.64	6.13	5.20	4.12	4.89	3.08	2.74	2.33	0.83	0.68	2.68
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	31.22%	34.05%	39.97%	39.30%	28.33%	-66.19%	39.49%	36.12%	6.62%	1.63%
Debt-free Net Working Capital to Revenue	0.00%	108.63%	92.15%	71.17%	57.43%	55.11%	-34.26%	50.01%	42.61%	15.01%	13.36%
Net Working Capital to Revenue	0.00%	108.63%	92.15%	71.17%	57.43%	55.11%	-34.26%	49.67%	42.24%	14.67%	12.88%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	96.16M	96.16M	83.61M	16.72M	16.72M	30.49M	30.66M	71.84M	374.21M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	96.16M	96.16M	83.61M	16.72M	16.72M	30.49M	30.66M	71.84M	374.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	96.16M	96.16M	83.61M	16.72M	16.72M	30.49M	30.66M	71.84M	374.21M
Normalized Net Operating Profit after Tax (NOPAT)	13	2.01	2.86	4.69	0.13	7.78	7.62	-9.46	-11	-9.59	-6.68
Normalized NOPAT Margin	13.04%	2.02%	2.89%	4.84%	0.14%	7.62%	9.39%	-15.13%	-19.63%	-15.58%	-15.26%
Pre Tax Income Margin	22.90%	-42.30%	-40.22%	-23.89%	-33.17%	-6.50%	-2.37%	-70.02%	-64.98%	-49.92%	-84.91%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	22.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	22.98%	-22.12%	-20.17%	-1.92%	0.00%	0.00%	-45.84%	-5.41%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for Trinity Biotech are available.

Financials Breakdown Chart

Trinity Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Trinity Biotech's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Trinity Biotech's net income appears to be on an upward trend, with a most recent value of -$33.31 million in 2025, falling from $22.19 million in 2015. The previous period was -$25.16 million in 2024. See Trinity Biotech's forecast for analyst expectations on what's next for the company.

Trinity Biotech's total operating income in 2025 was -$11.72 million, based on the following breakdown:

Total Gross Profit: $16.89 million
Total Operating Expenses: $28.61 million

Over the last 10 years, Trinity Biotech's total revenue changed from $100.20 million in 2015 to $43.79 million in 2025, a change of -56.3%.

Trinity Biotech's total liabilities were at $177.15 million at the end of 2025, a 27.9% increase from 2024, and a 25.8% increase since 2016.

In the past 9 years, Trinity Biotech's cash and equivalents has ranged from $3.69 million in 2023 to $77.11 million in 2016, and is currently $5.14 million as of their latest financial filing in 2025.

Over the last 10 years, Trinity Biotech's book value per share changed from 0.00 in 2015 to -0.38 in 2025, a change of -37.8%.

Related Companies

Financial statements for NASDAQ:TRIB last updated on 7/24/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trinity Biotech (TRIB) Financials

Financials Breakdown Chart

Trinity Biotech Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trinity Biotech (TRIB) Financials

Annual Income Statements for Trinity Biotech

Quarterly Income Statements for Trinity Biotech

Annual Cash Flow Statements for Trinity Biotech

Quarterly Cash Flow Statements for Trinity Biotech

Annual Balance Sheets for Trinity Biotech

Quarterly Balance Sheets for Trinity Biotech

Annual Metrics And Ratios for Trinity Biotech

Quarterly Metrics And Ratios for Trinity Biotech

Financials Breakdown Chart

Trinity Biotech Financials - Frequently Asked Questions

When does Trinity Biotech's fiscal year end?

How has Trinity Biotech's net income changed over the last 10 years?

What is Trinity Biotech's operating income?

How has Trinity Biotech's revenue changed over the last 10 years?

How much debt does Trinity Biotech have?

How much cash does Trinity Biotech have?

How has Trinity Biotech's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools